Brain Cancer – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, Brain Cancer - Pipeline Review, H1 2012, provides an overview of the Brain Cancer therapeutic pipeline. This report provides information on the therapeutic development for Brain Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Cancer. Brain Cancer - Pipeline Review, H1 2012 is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Brain Cancer.
- A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Brain Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Brain Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Brain Cancer pipeline depth and focus of Brain Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Brain Cancer Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Brain Cancer 12
Brain Cancer Therapeutics under Development by Companies 14
Brain Cancer Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 26
Comparative Analysis 26
Mid Clinical Stage Products 27
Comparative Analysis 27
Early Clinical Stage Products 28
Comparative Analysis 28
Discovery and Pre-Clinical Stage Products 29
Comparative Analysis 29
Brain Cancer Therapeutics – Products under Development by Companies 30
Brain Cancer Therapeutics – Products under Investigation by Universities/Institutes 34
Companies Involved in Brain Cancer Therapeutics Development 55
Abbott Laboratories 55
United Therapeutics Corporation 56
Eli Lilly and Company 57
Viralytics Ltd. 58
GlaxoSmithKline plc 59
Alkermes, Inc. 60
YM BioSciences Inc. 61
Aposense Ltd. 62
Advocate Health Care 63
Novartis AG 64
Dong-A Pharmaceutical Co., Ltd. 65
Nippon Shinyaku Co., Ltd. 66
Pfizer Inc. 67
Celgene Corporation 68
Geron Corporation 69
Advaxis, Inc. 70
4SC AG 71
GW Pharmaceuticals plc 72
Bionomics Limited 73
Peregrine Pharmaceuticals, Inc. 74
Critical Outcome Technologies Inc. 75
TopoTarget A/S 76
Mundipharma International Limited 77
Protox Therapeutics Inc. 78
e-Therapeutics plc 79
Morphotek, Inc. 80
Spectrum Pharmaceuticals, Inc. 81
Ambit Biosciences Corporation 82
Philogen S.p.A. 83
BioNumerik Pharmaceuticals, Inc. 84
Oncolin Therapeutics, Inc. 85
Pervasis Therapeutics, Inc. 86
Nobelpharma Co., Ltd. 87
Stemline Therapeutics, Inc. 88
BiPar Sciences, Inc. 89
Globeimmune, Inc. 90
Kinex Pharmaceuticals, LLC 91
to-BBB technologies BV 92
Archer Biosciences, Inc 93
Advanced Cancer Therapeutics 94
VectorLogics, Inc. 95
Brain Cancer – Therapeutics Assessment 96
Assessment by Monotherapy Products 96
Assessment by Combination Products 97
Assessment by Route of Administration 98
Assessment by Molecule Type 101
Drug Profiles 104
Hycamtin + Whole Brain Radiation Therapy - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Herceptin + Radiation Therapy - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Radiation Therapy + Temozolomide - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
TransMID - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Temozolomide + Radiation Therapy + Bevacizumab - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
Bevacizumab + Temozolomide + Radiation Therapy - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
memantine hydrochloride - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Methotrexate + Temozolomide + Thiotepa + Vincristine + Stem cell transplantation + Radiation Therapy - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 115
Carboplatin + Etoposide phosphate + Ifosfamide + Radiation therapy - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
Cisplatin+ Etoposide phosphate + Ifosfamide + Radiation therapy - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Sodium Thiosulfate - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
Carboplatin + Cyclophosphamide + Etoposide + Vincristine - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
Carboplatin + Cisplatin + Cyclophosphamide + Dactinomycin + Doxorubicin + Etoposide + Vincristine - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 125
Cisplatin + Cyclophosphamide + Vincristine Sulfate + Radiation Therapy + Autologous Stem Cell Transplantation - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 127
Carboplatin + Cyclophosphamide + Etoposide + Irinotecan + Temozolomide + Vincristine - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 130
Thalidomide + Radiation Therapy - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Leucovorin + Methotrexate + Thiotepa + Vincristine - Drug Profile 133
Product Description 133
Mechanism of Action 134
R&D Progress 135
porfimer sodium - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 136
Cisplatin + Etoposide + Ifosfamide + Lomustine + Methotrexate + Prednisone + Vincristine - Drug Profile 137
Product Description 137
Mechanism of Action 137
R&D Progress 138
Erlotinib Hydrochloride + Radiation Therapy - Drug Profile 139
Product Description 139
Mechanism of Action 139
R&D Progress 139
Radiation Therapy + Carmustine + Lomustine + Temozolomide - Drug Profile 140
Product Description 140
Mechanism of Action 140
R&D Progress 140
Carboplatin + Cisplatin - Drug Profile 142
Product Description 142
Mechanism of Action 142
R&D Progress 142
Carboplatin + Cyclophosphamide + Etoposide + Leucovorin + Methotrexate + Vincristine - Drug Profile 143
Product Description 143
Mechanism of Action 143
R&D Progress 144
Cyclophosphamide + Vincristine Sulfate - Drug Profile 145
Product Description 145
Mechanism of Action 145
R&D Progress 145
Cisplatin + Lomustine + Vincristine Sulfate - Drug Profile 146
Product Description 146
Mechanism of Action 146
R&D Progress 146
Carboplatin + Temozolomide + Thiotepa + Vincristine + Stem Cell Transplantion + Radiation Therapy - Drug Profile 148
Product Description 148
Mechanism of Action 148
R&D Progress 149
Carboplatin + Vincristine + Etoposide + Radiation Therapy - Drug Profile 150
Product Description 150
Mechanism of Action 150
R&D Progress 151
Cyclophosphamide + Etoposide + Vincristine + Radiation Therapy - Drug Profile 152
Product Description 152
Mechanism of Action 152
R&D Progress 153
Carboplatin + Cyclophosphamide + Etoposide + Vincristine + Doxorubicin + Cisplatin - Drug Profile 154
Product Description 154
Mechanism of Action 154
R&D Progress 155
Cisplatin + Lomustine + Vincristine Sulfate + Radiation Therapy - Drug Profile 156
Product Description 156
Mechanism of Action 156
R&D Progress 156
Filgrastim + Carboplatin + Cisplatin + Cyclophosphamide + Isotretinoin + Vincristine Sulfate + Radiation Therapy - Drug Profile 158
Product Description 158
Mechanism of Action 158
R&D Progress 158
Filgrastim + Carboplatin + Cisplatin + Cyclophosphamide + Vincristine Sulfate + Radiation therapy - Drug Profile 160
Product Description 160
Mechanism of Action 160
R&D Progress 160
Filgrastim + Cisplatin + Cyclophosphamide + Isotretinoin + Vincristine Sulfate + Radiation therapy - Drug Profile 162
Product Description 162
Mechanism of Action 162
R&D Progress 162
Brain Cancer Therapeutics – Discontinued Products 164
Brain Cancer Therapeutics - Dormant Products 165
Brain Cancer – Product Development Milestones 172
Featured News & Press Releases 172
Dec 22, 2011: Geron Initiates Phase II Trial Of GRN1005 In Brain Metastases Arising From Lung Cancer 172
Nov 15, 2011: Geron Presents Final Phase I Clinical Data On GRN1005 At AACR-NCI-EORTC 173
Nov 01, 2011: Telik Announces Ezatiostat Preclinical Presentation At 2011 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics 175
Sep 19, 2011: Researchers Discover Regulatory Protein As Potential Drug Target For Brain Tumors 175
Sep 08, 2011: Novartis Receives EU Approval For Votubia 176
Sep 06, 2011: DelMar Pharma Receives FDA IND Approval To Begin Clinical Trials With New Brain Cancer Treatment 177
Aug 04, 2011: Northwest Biotherapeutics Announces Further Expansion Of Clincal Sites In Ongoing Brain Cancer Trial 178
Jun 27, 2011: to-BBB Starts Clinical Trial In Patients With Brain Metastases 180
Jun 02, 2011: Stemline Therapeutics Announces Presentation Of Positive Phase I/II Trial Results With New Brain Cancer Vaccine At ASCO 2011 Annual Meeting 180
May 18, 2011: Northwest Biotherapeutics And Fraunhofer Partner For Clinical Trials And Compassionate Use Cases In Europe 181
Appendix 182
Methodology 182
Coverage 182
Secondary Research 182
Primary Research 182
Expert Panel Validation 183
Contact Us 183
Disclaimer 183

List of Tables

Number of Products Under Development for Brain Cancer, H1 2012 12
Products under Development for Brain Cancer – Comparative Analysis, H1 2012 13
Number of Products under Development by Companies, H1 2012 15
Number of Products under Development by Companies, H1 2012 (Contd..1) 16
Number of Products under Development by Companies, H1 2012 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2012 19
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 20
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 21
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 23
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 24
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 25
Comparative Analysis by Late Stage Development, H1 2012 26
Comparative Analysis by Mid Clinical Stage Development, H1 2012 27
Comparative Analysis by Early Clinical Stage Development, H1 2012 28
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 29
Products under Development by Companies, H1 2012 30
Products under Development by Companies, H1 2012 (Contd..1) 31
Products under Development by Companies, H1 2012 (Contd..2) 32
Products under Development by Companies, H1 2012 (Contd..3) 33
Products under Investigation by Universities/Institutes, H1 2012 34
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 35
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 36
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 37
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 38
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 39
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 40
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 41
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 42
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 43
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 44
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 45
Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 46
Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 47
Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 48
Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 49
Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 50
Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 51
Products under Investigation by Universities/Institutes, H1 2012 (Contd..18) 52
Products under Investigation by Universities/Institutes, H1 2012 (Contd..19) 53
Products under Investigation by Universities/Institutes, H1 2012 (Contd..20) 54
Abbott Laboratories, H1 2012 55
United Therapeutics Corporation, H1 2012 56
Eli Lilly and Company, H1 2012 57
Viralytics Ltd., H1 2012 58
GlaxoSmithKline plc, H1 2012 59
Alkermes, Inc., H1 2012 60
YM BioSciences Inc., H1 2012 61
Aposense Ltd., H1 2012 62
Advocate Health Care, H1 2012 63
Novartis AG, H1 2012 64
Dong-A Pharmaceutical Co., Ltd., H1 2012 65
Nippon Shinyaku Co., Ltd., H1 2012 66
Pfizer Inc., H1 2012 67
Celgene Corporation, H1 2012 68
Geron Corporation, H1 2012 69
Advaxis, Inc., H1 2012 70
4SC AG, H1 2012 71
GW Pharmaceuticals plc, H1 2012 72
Bionomics Limited, H1 2012 73
Peregrine Pharmaceuticals, Inc., H1 2012 74
Critical Outcome Technologies Inc., H1 2012 75
TopoTarget A/S, H1 2012 76
Mundipharma International Limited, H1 2012 77
Protox Therapeutics Inc., H1 2012 78
e-Therapeutics plc, H1 2012 79
Morphotek, Inc., H1 2012 80
Spectrum Pharmaceuticals, Inc., H1 2012 81
Ambit Biosciences Corporation, H1 2012 82
Philogen S.p.A., H1 2012 83
BioNumerik Pharmaceuticals, Inc., H1 2012 84
Oncolin Therapeutics, Inc., H1 2012 85
Pervasis Therapeutics, Inc., H1 2012 86
Nobelpharma Co., Ltd., H1 2012 87
Stemline Therapeutics, Inc., H1 2012 88
BiPar Sciences, Inc., H1 2012 89
Globeimmune, Inc., H1 2012 90
Kinex Pharmaceuticals, LLC, H1 2012 91
to-BBB technologies BV, H1 2012 92
Archer Biosciences, Inc, H1 2012 93
Advanced Cancer Therapeutics, H1 2012 94
VectorLogics, Inc., H1 2012 95
Assessment by Monotherapy Products, H1 2012 96
Assessment by Combination Products, H1 2012 97
Assessment by Stage and Route of Administration, H1 2012 100
Assessment by Molecule Type, H1 2012 103
Brain Cancer Therapeutics – Discontinued Products 164
Brain Cancer Therapeutics – Dormant Products 165
Brain Cancer Therapeutics – Dormant Products (Contd..1) 166
Brain Cancer Therapeutics – Dormant Products (Contd..2) 167
Brain Cancer Therapeutics – Dormant Products (Contd..3) 168
Brain Cancer Therapeutics – Dormant Products (Contd..4) 169
Brain Cancer Therapeutics – Dormant Products (Contd..5) 170
Brain Cancer Therapeutics – Dormant Products (Contd..6) 171

List of Figures

Number of Products under Development for Brain Cancer, H1 2012 12
Products under Development for Brain Cancer – Comparative Analysis, H1 2012 13
Products under Development by Companies, H1 2012 14
Products under Investigation by Universities/Institutes, H1 2012 18
Late Stage Products, H1 2012 26
Mid Clinical Stage Products, H1 2012 27
Early Clinical Stage Products, H1 2012 28
Discovery and Pre-Clinical Stage Products, H1 2012 29
Assessment by Monotherapy Products, H1 2012 96
Assessment by Combination Products, H1 2012 97
Assessment by Route of Administration, H1 2012 98
Assessment by Stage and Route of Administration, H1 2012 99
Assessment by Molecule Type, H1 2012 101
Assessment by Stage and Molecule Type, H1 2012 102